NYSE:GKOSMedical Equipment
How FDA Approval of Repeat iDose TR Use Will Impact Glaukos (GKOS) Investors
In late January 2026, Glaukos Corporation received FDA approval for an NDA labeling supplement that permits repeat administration of its long-duration iDose TR glaucoma implant, supported by clinical data showing safe and well-tolerated second treatments over 12 months.
This decision effectively positions iDose TR as a potentially longer-term, repeatable treatment option aimed at reducing non-compliance and side effects linked to traditional eye-drop therapies for glaucoma.
Next, we will...